Clinical trials: Type 1 or 2 Diabetes
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Diabetic Foot Ulcer, Type 1 Diabetes Mellitus
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2…
- Conditions
- Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer
- Trial name
- NCT06810726
- Testing
- Platelet Rich Plasma
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Estar Medical dba Medical Technologies, LTD
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety While Using Levemir®
This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions in Egypt.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00701155
- Testing
- insulin detemir
- Where
- Egypt
- Volunteers
- 3,593 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
- Trial name
- NCT00143247
- Testing
- Exubera® (inhaled insulin)
- Where
- 12 sites in United States
- Volunteers
- 173 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Diabetes (Insulin-requiring, Type 1 or Type 2)
Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management
New telemedicine systems have been designed to assist people suffering from diabetes in the management of their chronic disease. More recently the focus has been moving to portable systems equipped with Bluetooth.
- Trial name
- T+ (NCT00922376)
- Testing
- Mobile phone telehealth application: Think Positive (T+)
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- University College London Hospitals
Type 1 Diabetes, Type 2 Diabetes
A Trial of 18F-AV-133 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the safety and pancreas imaging properties of 18F-AV-133.
- Trial name
- NCT01515384
- Testing
- 18F-AV-133
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Diabetes Mellitus, Type 1, Type 2
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 or type 2 diabetes.
- Trial name
- STRIVE (NCT06865989)
- Testing
- Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 1
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542489
- Testing
- insulin detemir, insulin aspart, human soluble insulin
- Where
- Slovakia
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
- Trial name
- STRIVE 2 (NCT07579702)
- Testing
- Omnipod 5 System, Omnipod 6 System
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Insulet Corporation
Diabetic Foot, Foot Ulcer, Diabetic
Use of Santyl in Diabetic Foot Ulcers
This study is designed to test the hypothesis that daily treatment of diabetic foot ulcers with an enzymatic debriding agent, SANTYL, for up to 6 weeks will result in more rapid decrease in ulcer area than diabetic foot ulcers…
- Trial name
- NCT02581488
- Testing
- Santyl, Product containing silver
- Where
- 13 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Smith & Nephew, Inc.
Diabetes Mellitus, Type 2, Prediabetes or Diabetes
Pilot - Resistance Exercise for Inpatient Treatment in T2D
Type 2 Diabetes (T2D) is associated with prolonged hospitalization and an increased risk of readmission. Moreover, sedentary behavior and poor glycemic control may contribute to disease severity and mortality.
- Conditions
- Diabetes Mellitus, Type 2, Prediabetes or Diabetes, Prediabetes
- Trial name
- P-REFIT-T2D (NCT06547541)
- Testing
- Exercise
- Where
- 2 sites in Denmark
- Volunteers
- 4 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes, Type I, Diabetes, Type II
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Coronary vascular dysfunction is highly prevalent among patients with known or suspected Coronary Artery Disease (CAD)1, increases the severity of inducible myocardial ischemia (beyond the effects of upstream coronary…
- Conditions
- Diabetes, Type I, Diabetes, Type II, Angina, Coronary Artery Disease
- Trial name
- RAND-CFR (NCT01754259)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Brigham and Women's Hospital
Type 1 Diabetes, Type 2 Diabetes
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes.
- Trial name
- NCT04484779
- Testing
- IIM System, Insulin Lispro and/or Insulin Glargine
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Diabetes
The Different Response of Endocrine Hormones to Hypoglycemia in Patients With Type 1 or Type 2 Diabetes
Endocrine hormones, not only blood glucose responsive hormones, but also sexual hormones, thyroid hormones, growth hormones and so on, may have response and activites in hypoglycemia.
- Trial name
- NCT05290207
- Testing
- The hyperinsulinaemic hypoglycaemic clamp
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S